Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder.
Attention Deficit Hyperactivity Disorder
Treatment
Viloxazine
Journal
Health psychology research
ISSN: 2420-8124
Titre abrégé: Health Psychol Res
Pays: United States
ID NLM: 101633445
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
28
9
2022
pubmed:
29
9
2022
medline:
29
9
2022
Statut:
epublish
Résumé
Attention deficit hyperactivity disorder (ADHD) is a widely diagnosed neurodevelopmental disorder giving rise to symptoms of hyperactivity, impulsivity, and inattentiveness that can impair daily functioning. Stimulants, such as methylphenidate and amphetamines, are the mainstay of treatment for ADHD. However, nonstimulant drugs such as viloxazine, atomoxetine, guanfacine, and clonidine are becoming more popular due to minimal adverse effects when compared to stimulants. Viloxazine is a selective norepinephrine reuptake inhibitor (NRI) originally used to treat depression in adults with activity in both the noradrenergic as well as serotonergic pathways. Studies have demonstrated its efficacy for its use in the treatment of ADHD. Unlike stimulants, viloxazine has a decreased chance of substance abuse, drug dependance, and withdrawal symptoms upon the cessation of therapy. Additionally, dopamine levels in the nucleus accumbens after treatment with viloxazine are elevated considerably less in comparison with traditional stimulant ADHD treatments. Viloxazine provides an alternative, nonstimulant approach to treating ADHD. Viloxazine is a recently approved, non-stimulant medication functions by inhibiting the uptake of norepinephrine which has been seen to be decreased in patients with ADHD. When patients do not respond to first-line stimulants, cannot tolerate the side effects, or have contraindications to stimulants, viloxazine may be a nonstimulant option offering patients an increasing arsenal of medications to treat ADHD.
Identifiants
pubmed: 36168642
doi: 10.52965/001c.38360
pii: 38360
pmc: PMC9501833
doi:
Types de publication
Journal Article
Langues
eng
Pagination
38360Déclaration de conflit d'intérêts
There are no conflict of interests with the authors.
Références
J Exp Pharmacol. 2020 Aug 25;12:285-300
pubmed: 32943948
Pediatr Rev. 2001 Jun;22(6):183-90
pubmed: 11389305
Xenobiotica. 2020 Nov;50(11):1285-1300
pubmed: 32394778
J Am Acad Child Adolesc Psychiatry. 2014 Oct;53(10):1092-101
pubmed: 25245353
J Clin Child Adolesc Psychol. 2016 Jul-Aug;45(4):396-415
pubmed: 26882332
Front Psychiatry. 2021 Dec 17;12:789982
pubmed: 34975586
Cochrane Database Syst Rev. 2014 Sep 19;(9):CD006997
pubmed: 25238582
Neurology. 2002 Feb 26;58(4):527-36
pubmed: 11865128
Clin Ther. 2021 Apr;43(4):684-700
pubmed: 33750646
Clin Toxicol (Phila). 2007;45(1):51-5
pubmed: 17357382
J Am Acad Child Adolesc Psychiatry. 2009 Mar;48(3):240-248
pubmed: 19242289
Pediatrics. 2019 Oct;144(4):
pubmed: 31570648
CNS Spectr. 2022 Apr;27(2):199-207
pubmed: 33121553
Cochrane Database Syst Rev. 2018 May 09;5:CD012069
pubmed: 29744873
J Am Acad Child Adolesc Psychiatry. 2009 Feb;48(2):155-65
pubmed: 19106767
J Clin Psychopharmacol. 2021 Mar-Apr 01;41(2):155-162
pubmed: 33587403
Eur J Neurosci. 2016 Jun;43(12):1661-73
pubmed: 27038339
J Am Acad Child Adolesc Psychiatry. 2015 Nov;54(11):916-25.e2
pubmed: 26506582
J Clin Psychiatry. 2004;65 Suppl 3:38-45
pubmed: 15046534
Neuropharmacology. 1998 Dec;37(12):1603-10
pubmed: 9886683
Clin Ther. 2016 Mar;38(3):595-602
pubmed: 26874787
Expert Opin Emerg Drugs. 2020 Dec;25(4):395-407
pubmed: 32938246
Med Lett Drugs Ther. 2015 Mar 16;57(1464):37-40
pubmed: 25758544
Child Neuropsychol. 2018 May;24(4):427-450
pubmed: 28277151
Paediatr Drugs. 2021 Jul;23(4):403-409
pubmed: 34036533
Front Hum Neurosci. 2019 Feb 11;13:42
pubmed: 30804772
J Clin Psychopharmacol. 2021 Jul-Aug 01;41(4):370-380
pubmed: 34181360
Clin Psychol Rev. 2014 Apr;34(3):218-32
pubmed: 24632046
Pediatrics. 2015 Dec;136(6):1144-53
pubmed: 26598454
J Atten Disord. 2015 Nov;19(11):931-43
pubmed: 24097847
Lancet. 2020 Feb 8;395(10222):450-462
pubmed: 31982036
Dtsch Arztebl Int. 2017 Mar 3;114(9):149-159
pubmed: 28351467
J Am Acad Child Adolesc Psychiatry. 1999 Dec;38(12):1551-9
pubmed: 10596256
Drug Saf. 2003;26(10):729-40
pubmed: 12862507
Pediatr Clin North Am. 2011 Feb;58(1):99-120, xi
pubmed: 21281851
J Am Acad Child Adolesc Psychiatry. 2006 Apr;45(4):408-14
pubmed: 16601645
Psychopharmacol Bull. 2021 Mar 16;51(2):43-64
pubmed: 34092822
J Clin Psychiatry. 2020 Oct 13;81(6):
pubmed: 33049804
J Clin Pharmacol. 2021 Dec;61(12):1626-1637
pubmed: 34269426
J Am Acad Child Adolesc Psychiatry. 2008 Feb;47(2):180-188
pubmed: 18182963
Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I7-30
pubmed: 15322953
J Child Psychol Psychiatry. 2016 Jun;57(6):717-28
pubmed: 26871297
J Am Acad Child Adolesc Psychiatry. 2009 Sep;48(9):884-893
pubmed: 19625978
Psychopharmacology (Berl). 1986;90(3):295-8
pubmed: 3097715
CNS Drugs. 2017 Jul;31(7):625-638
pubmed: 28667569
Paediatr Child Health. 2008 Jan;13(1):19-24
pubmed: 19119348
Curr Allergy Asthma Rep. 2011 Dec;11(6):454-64
pubmed: 21968618
Evid Rep Technol Assess (Summ). 1999 Nov;(11):i-viii, 1-341
pubmed: 10790990
Neuropharmacology. 1997 Apr-May;36(4-5):609-20
pubmed: 9225286
Paediatr Child Health. 2018 Nov;23(7):462-472
pubmed: 30681665
J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):21-31
pubmed: 18174822
J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894-921
pubmed: 17581453
J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):242-51
pubmed: 17242628
Eur J Pediatr. 2014 Dec;173(12):1631-4
pubmed: 24233333
J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1284-1293
pubmed: 17023867
Clin Ther. 2020 Aug;42(8):1452-1466
pubmed: 32723670
J Am Acad Child Adolesc Psychiatry. 2014 Feb;53(2):174-87
pubmed: 24472252
J Am Acad Child Adolesc Psychiatry. 2006 Feb;45(2):192-202
pubmed: 16429090
Neuropharmacology. 2004;47 Suppl 1:227-41
pubmed: 15464140
Arch Dis Child Educ Pract Ed. 2008 Apr;93(2):58-65
pubmed: 18356307
J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26
pubmed: 26859445
Int J Methods Psychiatr Res. 2005;14(4):186-201
pubmed: 16395872
Eur Neuropsychopharmacol. 1997 Apr;7 Suppl 1:S23-35; discussion S71-3
pubmed: 9169308
J Neurosci. 2000 Aug 1;20(15):RC89
pubmed: 10899176
JAMA. 2016 May 10;315(18):1997-2008
pubmed: 27163988
Eur Child Adolesc Psychiatry. 2000;9 Suppl 1:I51-9
pubmed: 11140780
J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):74-85.e2
pubmed: 22176941
BMC Med. 2011 Jun 10;9:72
pubmed: 21658285
CNS Drugs. 2016 Jul;30(7):603-28
pubmed: 27290715
Curr Opin Pediatr. 2005 Apr;17(2):265-74
pubmed: 15800424
J Pediatr. 2006 Jun;148(6):831-4
pubmed: 16769398
J Psychopharmacol. 2014 Mar;28(3):204-11
pubmed: 23438503
J Am Acad Child Adolesc Psychiatry. 2008 Feb;47(2):209-218
pubmed: 18176331
Arch Dis Child. 2014 Sep;99(9):866-72
pubmed: 24748641
Cochrane Database Syst Rev. 2016 Feb 04;2:CD009996
pubmed: 26844979
Arch Dis Child. 2005 Feb;90 Suppl 1:i26-9
pubmed: 15665154
Pediatrics. 2011 Jun;127(6):e1406-13
pubmed: 21555501
Nat Rev Dis Primers. 2015 Aug 06;1:15020
pubmed: 27189265
J Atten Disord. 2020 Jan;24(2):348-358
pubmed: 30924702
Psychopharmacology (Berl). 2005 Feb;177(4):448-58
pubmed: 15289999
J Am Acad Child Adolesc Psychiatry. 1996 Oct;35(10):1314-21
pubmed: 8885585
Clin Drug Investig. 2021 Feb;41(2):149-159
pubmed: 33368026
Drug Saf. 2008;31(4):345-54
pubmed: 18366245
Child Adolesc Ment Health. 2016 Nov;21(4):192-200
pubmed: 32680336
Eur J Drug Metab Pharmacokinet. 1982 Jan-Mar;7(1):65-8
pubmed: 7067726
Am J Psychiatry. 2006 Apr;163(4):716-23
pubmed: 16585449
Subst Use Misuse. 2005;40(13-14):1955-81, 2043-8
pubmed: 16282088
Cochrane Database Syst Rev. 2018 Jun 26;6:CD007990
pubmed: 29944175
J Am Acad Child Adolesc Psychiatry. 2009 Feb;48(2):176-85
pubmed: 20040824
Yale J Biol Med. 2011 Mar;84(1):27-33
pubmed: 21451781
CNS Drugs. 2021 Jun;35(6):643-653
pubmed: 34003459